Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.

Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Am J Hematol. 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241.

PMID:
22237692
2.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Review.

PMID:
16919893
3.

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H.

Blood. 2011 May 26;117(21):5710-8. doi: 10.1182/blood-2010-07-293761.

PMID:
21447832
4.

Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.

Thiele J, Kvasnicka HM, Zankovich R, Diehl V.

Haematologica. 2000 Nov;85(11):1126-34.

PMID:
11064463
5.

The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Thiele J, Kvasnicka HM.

Curr Hematol Malig Rep. 2009 Jan;4(1):33-40. doi: 10.1007/s11899-009-0005-6.

PMID:
20425436
6.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298.

PMID:
21747083
8.

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.

Barbui T, Thiele J, Vannucchi AM, Tefferi A.

Leukemia. 2013 Oct;27(10):1953-8. doi: 10.1038/leu.2013.74. Review.

PMID:
23467025
9.

[The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].

Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jan;33(1):25-30. Chinese.

PMID:
22575188
10.

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.

Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC.

Histopathology. 2010 May;56(6):758-67. doi: 10.1111/j.1365-2559.2010.03545.x.

PMID:
20546341
11.

MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis.

Ponce CC, Chauffaille Mde L, Ihara SS, Silva MR.

Leuk Res. 2012 Jan;36(1):93-7. doi: 10.1016/j.leukres.2011.06.024.

PMID:
21752469
12.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
13.

Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.

Muth M, Engelhardt BM, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe HH, Bock O.

Ann Hematol. 2011 Jan;90(1):33-40. doi: 10.1007/s00277-010-1024-z.

PMID:
20625903
14.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
16.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005.

PMID:
19616600
17.

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P.

Diagn Pathol. 2015 Apr 16;10:29. doi: 10.1186/s13000-015-0269-1.

PMID:
25885405
18.

Prodromal myeloproliferative neoplasms: the 2008 WHO classification.

Kvasnicka HM, Thiele J.

Am J Hematol. 2010 Jan;85(1):62-9. doi: 10.1002/ajh.21543. Review.

PMID:
19844986
19.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H.

Haematologica. 2012 Mar;97(3):360-5. doi: 10.3324/haematol.2011.047811.

PMID:
22058215
20.
Items per page

Supplemental Content

Support Center